The recent revolution in –omics technology and the advent of targeted and immune therapies have increased the interest in molecular biomarkers capable of predicting the diagnostic, the clinical outcome of cancer patients or the response to specific therapies. The development of stratified medicine implies the segmentation of common cancers in small groups of tumors with specific abnormalities. A new generation of clinical trial designs requiring repeated biomarker measurements and surrogate clinical endpoints is needed to evaluate treatment effects in trials with limited sample sizes (research theme 1 "Clinical Trial Methodology"). Large-scale collaborative individual patient data (IPD) meta-analyses are useful tools to provide high level of evidence on the efficacy and toxicity of anti-cancer therapies in molecularly defined strata (theme 2 "Meta-analysis of treatments and biomarkers”). With the increasing number of therapies available for a specific indication in oncology, methods for network meta-analysis are being developed to compare their effectiveness. Because of the high costs associated with the tandem diagnostic and therapeutic medicine, economic analyses will be needed to evaluate the strategy associating the biomarkers with the molecularly targeted treatments, which represents a new field of research (theme 3 "Economic evaluation of treatments and biomarkers"). Once a potential biomarker has been identified for the prediction of diagnosis or clinical outcome of patients, an evidence-based evaluation implies careful replication in other cohorts. Advances in molecular genetics and in the knowledge of pathology of cancer are re-shaping the traditional methods in clinical epidemiology (theme 4 "Development and validation of biomarkers "). The statistical software packages developed in the team are available to the scientific community on the website https://github.com/Oncostat


Hôpital Gustave Roussy, Bat. B2M

114 rue Edouard Vaillant
94805 Villejuif

Principaux Financeurs
Union Européenne



Dernières publications

Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Danlos, F. X.; Voisin, A. L.; Dyevre, V.; Michot, J. M.; Routier, E.; Taillade, L.; Champiat, S.; Aspeslagh, S.; Haroche, J.; Albiges, L.; Massard, C.; Girard, N.; Dalle, S.; Besse, B.; Laghouati, S.; Soria, J. C.; Mateus, C.; Robert, C.; Lanoy, E.; Marabelle, A.; Lambotte, O.. Eur J Cancer. 2018; 21-29: p.21-29. doi:10.1016/j.ejca.2017.12.008
Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas. Delahousse, J.; Verlingue, L.; Broutin, S.; Legoupil, C.; Touat, M.; Doucet, L.; Ammari, S.; Lacroix, L.; Ducreux, M.; Scoazec, J. Y.; Malka, D.; Paci, A.; Hollebecque, A.. Eur J Cancer. 2018; 83-91: p.83-91. doi:10.1016/j.ejca.2017.11.024
Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer. Devarakonda, S.; Rotolo, F.; Tsao, M. S.; Lanc, I.; Brambilla, E.; Masood, A.; Olaussen, K. A.; Fulton, R.; Sakashita, S.; McLeer-Florin, A.; Ding, K.; Le Teuff, G.; Shepherd, F. A.; Pignon, J. P.; Graziano, S. L.; Kratzke, R.; Soria, J. C.; Seymour, L.; Govindan, R.; Michiels, S.. J Clin Oncol. 2018; JCO2018781963: p.JCO2018781963. doi:10.1200/JCO.2018.78.1963
Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trial. Arnedos, M.; Bayar, M. A.; Cheaib, B.; Scott, V.; Bouakka, I.; Valent, A.; Adam, J.; Leroux-Kozal, V.; Marty, V.; Rapinat, A.; Mazouni, C.; Sarfati, B.; Bieche, I.; Balleyguier, C.; Gentien, D.; Delaloge, S.; Lacroix-Triki, M.; Michiels, S.; Andre, F.. Ann Oncol. 2018; 1755-1762: p.1755-1762. doi:10.1093/annonc/mdy202
Magnetic Resonance-based Response Assessment and Dose Adaptation in Human Papilloma Virus Positive Tumors of the Oropharynx treated with Radiotherapy (MR-ADAPTOR): An R-IDEAL stage 2a-2b/Bayesian phase II trial. Bahig, H.; Yuan, Y.; Mohamed, A. S. R.; Brock, K. K.; Ng, S. P.; Wang, J.; Ding, Y.; Hutcheson, K.; McCulloch, M.; Balter, P. A.; Lai, S. Y.; Al-Mamgani, A.; Sonke, J. J.; van der Heide, U. A.; Nutting, C.; Li, X. A.; Robbins, J.; Awan, M.; Karam, I.; Newbold, K.; Harrington, K.; Oelfke, U.; Bhide, S.; Philippens, M. E. P.; Terhaard, C. H. J.; McPartlin, A. J.; Blanchard, P.; Garden, A. S.; Rosenthal, D. I.; Gunn, G. B.; Phan, J.; Cazoulat, G.; Aristophanous, M.; McSpadden, K. K.; Garcia, J. A.; van den Berg, C. A. T.; Raaijmakers, C. P. J.; Kerkmeijer, L.; Doornaert, P.; Blinde, S.; Frank, S. J.; Fuller, C. D.. Clin Transl Radiat Oncol. 2018; 19-23: p.19-23. doi:10.1016/j.ctro.2018.08.003


Apport clinique des méta-analyses dans les cancers ORL localement avancés. Dirigée par Jean-Pierre Pignon & Pierre Blanchard. Lacas Benjamin. []: Paris Sud; .
Essais cliniques randomisés en oncologie en présence de sous-types rares identifiés par biomarqueur. Dirigée par Stefan Michiels. Bayar Mohamed Amine. []: Paris Sud; .
Identification de sous-groupes à l'aide de biomarqueurs de grande dimension dans les essais randomisés. Dirigée par Stefan Michiels & Federico Rotolo. Belhechmi Shaima . []: Paris Sud; .
Evaluation du coût et de la qualité de vie des patients atteints de mélanome métastatique : analyse des données de la cohorte MELBASE en vie réelle. Dirigée par Stefan Michiels & Isabelle Borget. Kandel Marguerite. []: Paris Sud; .